Boehringer Ingelheim is finding it difficult to get the stink of the troubled Ben Venue Bedford, OH, operations off its shoes. It closed the site last year and sold it last month but is still having to recall products produced there that might be contaminated.
Legal experts have insisted there is no way that a $9 billion punitive damage award against Takeda Pharmaceutical and Eli Lilly for hiding Actos risks can stand. But the two companies are still sweating that one out after a federal judge refused to throw out the verdict and its mammoth award on Thursday.
Sleep aids have landed in the safety spotlight recently, with regulatory agencies lowering dosages on some meds to ease side effect worries. But overmedication has its own set of risks, and a new study says those resulted in a doubling of emergency department visits between 2005 and 2010.
There used to be a legal specialty built by plaintiff attorneys around filing lawsuits against antidepressant makers and then settling them. But the black box warning put on antidepressants in 2004 has turned out to be a shroud for the once lucrative legal business.
Teva Pharmaceutical Industries, whose manufacturing operation is being signifcantly pared down, is recalling one lot of its generic Parkinson's combo drug carbidopa/levodopa because it may have too much active pharmaceutical ingredient.
Pfizer is recalling two lots of its 40 mg/ mL, 1 mL single-dose vials of its anti inflammatory product Depo-Medrol.
Merck's already won two bellwether suits over femur fractures suffered by Fosamax patients. But is that enough to get the remaining 500 or so cases tossed out?
The contenders to develop new methods of tackling the problem of opioid addiction should receive a boost from a new study by the federal Agency for Healthcare Research & Quality, which found that the overuse of pain medications has resulted in a 5% average annual increase in adult hospital stays between 1993 and 2012.
Becton, Dickinson and Company today announced that its BD AutoShield Duo pen for the delivery of insulin and diabetes drugs is now available in retail pharmacies.
Cytori Therapeutics hit the brakes on a pair of clinical trials to find out why three patients in the study suffered from "cerebrovascular" events after they were treated with the biotech's experimental stem cell treatment. The San Diego-based biotech's shares plunged more than 30% in after-hours trading after putting out word of the hold in a late release.